Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan

BACKGROUND: The NAPOLI-1 trial demonstrated that liposomal irinotecan in combination with fluorouracil (5-FU) and leucovorin (LV) prolonged survival with a manageable safety profile in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Front Oncol
Glavni autori: Yu, Kenneth H., Hendifar, Andrew E., Alese, Olatunji B., Draper, Amber, Abdelrahim, Maen, Burns, Ethan, Khan, Gazala, Cockrum, Paul, Bhak, Rachel H., Nguyen, Catherine, DerSarkissian, Maral, Duh, Mei Sheng, Bahary, Nathan
Format: Artigo
Jezik:Inglês
Izdano: Frontiers Media S.A. 2021
Teme:
Oncology
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8319949/
https://ncbi.nlm.nih.gov/pubmed/34336666
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.678070
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items